Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
CSPC Pharmaceutical Group ( (HK:1093) ) has provided an update.
CSPC Pharmaceutical Group announced that its new drug application for KN026 (Anbenitamab Injection), co-developed with Jiangsu Alphamab Oncology, has been accepted by China’s National Medical Products Administration. This drug, an anti-HER2 bispecific antibody, is intended for the treatment of HER2-positive gastric cancer and has shown promising results in clinical trials, including improved survival rates and safety profiles. The acceptance marks a significant advancement in CSPC’s efforts to provide effective second-line treatments for gastric cancer, with ongoing trials for other solid tumors.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$12.90 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group is a prominent company in the pharmaceutical industry, focusing on the development and production of therapeutic biological products. The company is engaged in innovative drug research and development, with a market focus on addressing critical medical needs, particularly in oncology.
Average Trading Volume: 184,342,251
Technical Sentiment Signal: Buy
Current Market Cap: HK$125.8B
For a thorough assessment of 1093 stock, go to TipRanks’ Stock Analysis page.